IONTAS and Adaptate Biotherapeutics collaborate to identify optimised antibodies for novel cancer targets

This article was originally published here

The agreement is to generate and optimise antibodies for novel immuno-oncology targets, including access to IONTAS’ proprietary Mammalian Display technology to select antibodies with optimal biophysical properties. IONTAS’

The post IONTAS and Adaptate Biotherapeutics collaborate to identify optimised antibodies for novel cancer targets appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply